Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Inclusion Criteria:

- Male or female, 18 to 75 years of age.

- Healthy volunteers must be in good general health.

- Subjects with hepatic impairment must be judged to be in stable condition.

- Subjects of childbearing potential must agree to use hormonal or two forms of
nonhormonal birth control during the study.

- Female subjects must not be pregnant, given birth within 1 year of study start, or
breastfeeding.

- Have a body mass index (BMI) of 18 to 40 kg/m2 (both inclusive).

Exclusion Criteria:

- Report more than two alcoholic beverages daily or more than 14 alcoholic beverages
weekly withing 7 days of study start.

- Have a known history of neuroleptic malignant syndrome.

- Have a positive human immunodeficiency virus (HIV) antibody result at screening or
have a history of positive result.

- Have received an investigational drug within 30 days before screening or plan to use
an investigational drug (other than NBI-98854) during the study.

- Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

- Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of
study start.

- Have had previous exposure with NBI-98854.